Adaptive Biotechnologies Corp
Several biotech stocks hit 52-week highs on September 16, 2026. BlossomHill Therapeutics rose 18% due to positive trial data. Adaptive Biotechnologies, Illumina, Ceribell, and Neogen also reached highs. Illumina will join the S&P 500 in September.
Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.
OWEN KATEY EINTERZ sold 9,615 shares of Adaptive Biotechnologies Corp (ADPT) at $26.00 ($0.25M total) on 2026-08-26.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ADPT (Adaptive Biotechnologies Corp). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent ADPT coverage spans insider activity, market movers and financial news.
In the last 30 days, ADPT insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($7.8M). The most active reporter was HERSHBERG ROBERT with 2 filings.
Mentioned only as part of a broader rally, no specific catalyst disclosed.
Revenue guidance and segment performance support a continued rally.
Insider sale may signal slight negative sentiment but size is modest relative to market cap.
Significant insider sell by a director may signal concerns about near-term valuation.
Large insider sell may weigh on ADPT.
AlphAI scores every news story that mentions ADPT with an AI model for sentiment and relevance, and aggregates insider trades from Adaptive Biotechnologies Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Several biotech stocks hit 52-week highs on September 16, 2026. BlossomHill Therapeutics rose 18% due to positive trial data. Adaptive Biotechnologies, Illumina, Ceribell, and Neogen also reached highs. Illumina will join the S&P 500 in September.
2 min readBiotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.
3 min readOWEN KATEY EINTERZ sold 9,615 shares of Adaptive Biotechnologies Corp (ADPT) at $26.00 ($0.25M total) on 2026-08-26.
1 min readHERSHBERG ROBERT sold 30,664 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $24.40 ($24.39–$24.41, $0.75M total) across 2 trades on 2026-08-18.
1 min readOn Wednesday, notable insider trading activity occurred in U.S. stocks. Zentalis Pharmaceuticals (ZLAB) saw a major purchase by Walters Group, while Bakkt (BKKT), Universal Safety Products (UNSP), Advanced Flower Capital (AFCG), and Brilliant Earth (BID) also had significant insider buys. Astera Labs (ALAB), Adaptive Biotechnologies (ADPT), and PACS Group (PACS) reported insider sales, some mandatory for tax purposes. InvestingPro analysis suggests some stocks are undervalued or overvalued.
3 min readROBINS CHAD M (CEO and Chairman) sold 600,000 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $24.80 ($24.48–$25.57, $14.88M total) across 4 trades over 2026-08-17 to 2026-08-18.
1 min readNEUPERT PETER M sold 124,690 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $25.15 ($25.10–$25.23, $3.14M total) across 3 trades on 2026-08-17.
1 min readAdaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results SEATTLE, Jul. 29, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gene
6 min readROBINS HARLAN S (Chief Scientific Officer) sold 492,400 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $21.89 ($21.72–$22.12, $10.78M total) across 2 trades on 2026-07-21 under a Rule 10b5-1 trading plan.
2 min readInvesting.com reports BTIG analyst Mark Massaro previewed seven specialty labs and diagnostics stocks as valuations rise. BTIG rates Guardant Health (GH) Buy, $190 target; Natera (NTRA) Buy, $290; BillionToOne (BLLN) Buy, $142; GeneDx (WGS) Buy, $90; Adaptive Biotechnologies (ADPT) Buy, $24; Tempus AI (TEM) Buy, $80; Caris (CAI) Buy, $32, with Q2 expectations and volume or catalyst updates.
5 min read
